177 related articles for article (PubMed ID: 38390939)
1. The Gut Microbiome Correlated to Chemotherapy Efficacy in Diffuse Large B-Cell Lymphoma Patients.
Xu ZF; Yuan L; Zhang Y; Zhang W; Wei C; Wang W; Zhao D; Zhou D; Li J
Hematol Rep; 2024 Jan; 16(1):63-75. PubMed ID: 38390939
[TBL] [Abstract][Full Text] [Related]
2. Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma.
Diefenbach CS; Peters BA; Li H; Raphael B; Moskovits T; Hymes K; Schluter J; Chen J; Bennani NN; Witzig TE; Ahn J
Blood Adv; 2021 Mar; 5(5):1194-1198. PubMed ID: 33635332
[TBL] [Abstract][Full Text] [Related]
3. The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma.
Lin Z; Mao D; Jin C; Wang J; Lai Y; Zhang Y; Zhou M; Ge Q; Zhang P; Sun Y; Xu K; Wang Y; Zhu H; Lai B; Wu H; Mu Q; Ouyang G; Sheng L
Front Immunol; 2023; 14():1105293. PubMed ID: 36891300
[TBL] [Abstract][Full Text] [Related]
4. Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients.
Yuan L; Wang W; Zhang W; Zhang Y; Wei C; Li J; Zhou D
Front Microbiol; 2021; 12():646361. PubMed ID: 33927704
[TBL] [Abstract][Full Text] [Related]
5. The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma.
Yoon SE; Kang W; Choi S; Park Y; Chalita M; Kim H; Lee JH; Hyun DW; Ryu KJ; Sung H; Lee JY; Bae JW; Kim WS; Kim SJ
Blood; 2023 May; 141(18):2224-2238. PubMed ID: 36724450
[TBL] [Abstract][Full Text] [Related]
6. Integration analysis of tumor metagenome and peripheral immunity data of diffuse large-B cell lymphoma.
Zhang Y; Han S; Xiao X; Zheng L; Chen Y; Zhang Z; Gao X; Zhou S; Yu K; Huang L; Fu J; Hong Y; Jiang J; Qian W; Yang H; Shen J
Front Immunol; 2023; 14():1146861. PubMed ID: 37234150
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers.
Stern JM; Moazami S; Qiu Y; Kurland I; Chen Z; Agalliu I; Burk R; Davies KP
Urolithiasis; 2016 Oct; 44(5):399-407. PubMed ID: 27115405
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
9. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
10. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
11. The Dark Side of Pyroptosis of Diffuse Large B-Cell Lymphoma in B-Cell Non-Hodgkin Lymphoma: Mediating the Specific Inflammatory Microenvironment.
Wang W; Xu SW; Teng Y; Zhu M; Guo QY; Wang YW; Mao XL; Li SW; Luo WD
Front Cell Dev Biol; 2021; 9():779123. PubMed ID: 34805183
[No Abstract] [Full Text] [Related]
12. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
[TBL] [Abstract][Full Text] [Related]
13. Identifying
Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
PeerJ; 2023; 11():e16618. PubMed ID: 38099311
[TBL] [Abstract][Full Text] [Related]
14. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with
Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y
Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498
[TBL] [Abstract][Full Text] [Related]
15. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
16. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
17. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
18. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
[No Abstract] [Full Text] [Related]
20. An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy.
Hu J; Xu J; Yu M; Gao Y; Liu R; Zhou H; Zhang W
J Transl Med; 2020 Mar; 18(1):144. PubMed ID: 32228625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
